16.03.2017 • News

Wacker Reduces Stake in Siltronic

“Given the favourable market situation in the semiconductor industry, we saw...
“Given the favourable market situation in the semiconductor industry, we saw an opportunity to significantly reduce Wacker’s stake in Siltronic and, as planned, become a non-controlling shareholder,” said CEO Rudolf Staudigl. Despite the sale, the company remains a major shareholder in Siltronic.

Germany’s Wacker Group has reduced its stake in subsidiary Siltronic from 51.8% to 30.8%. The group sold 6.3 million shares to institutional investors for €55.85 per share, giving gross proceeds of about €352 million.

 “Given the favourable market situation in the semiconductor industry, we saw an opportunity to significantly reduce Wacker’s stake in Siltronic and, as planned, become a non-controlling shareholder,” said CEO Rudolf Staudigl. Despite the sale, the company remains a major shareholder in Siltronic.

In separate news, the Munich-based family-owned chemical producer has announced it will spend about €85 million to build another plant for silicon metal at its site in Holla, Norway. Completion is expected during the first half of 2019.

Wacker also said it will expand its silicone production in Brazil. An investment of around €7 million will be made in a multi-purpose facility to manufacture antifoam compounds and functional silicone fluids at its site in Jandira, near São Paulo.

The silicone fluids reactor is scheduled for completion in the second quarter of 2017 while the antifoam compounds unit is due to go on stream by the end of the year. Wacker said the expansion is in response to growing regional demand for specialty silicones in the textile, paper, household, personal care and cosmetics industries.

Annual capacity figures for both projects were not disclosed.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.